Medicamen Biotech Share Price

Medicamen Biotech Share Price

  • 466.357.96 (1.74%)
  • Closed
  • As On: 01 Feb, 2025, 03:40 PM IST
Loading...
Open458.00
High474.35
Low452.05
Prev Close458.40
Volume6,700
VWAP(₹)462.87

Medicamen Bio share price insights

  • Beating 3 Yr Revenue CAGR

    Company's annual revenue growth of 26.72% outperformed its 3 year CAGR of 16.79%. (Source: Consolidated Financials)
  • Stock Returns vs Nifty Smallcap 100

    Stock gave a 3 year return of -43.88% as compared to Nifty Smallcap 100 which gave a return of 48.97%. (as of last trading session)
  • Employee & Interest Expense

    Company has spent 2.45% of its operating revenues towards interest expenses and 16.77% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
  • Stock Returns vs Nifty Pharma

    Stock generated -43.88% return as compared to Nifty Pharma which gave investors 62.52% return over 3 year time period. (as of last trading session)
  • Medicamen Bio Share Price Update

    Medicamen Biotech Ltd. share price moved up by 1.74% from its previous close of Rs 458.40. Medicamen Biotech Ltd. stock last traded price is 466.35

    Share PriceValue
    Today/Current/Last466.35
    Previous Day458.40

Found Insights useful?

Medicamen Bio Share Price Returns

1 Day1.74%
1 Month-9.0%
3 Months-13.04%
1 Year-13.63%
3 Years-42.28%
5 YearsN.A.

Key Metrics

PE Ratio(x)83.68
EPS - TTM(₹)5.48
MCap(₹ Cr.)582.84
MCap Rank84
PB Ratio(x)2.83
Div Yield(%)0.22
Face Value(₹)10.00
52W High(₹)630.00
52W Low(₹)355.45
MCap/Sales2.72
Beta(1 Month)-
BV/Share(₹)162.79

Medicamen Bio Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

Medicamen Bio Share Analysis

EARNINGS
FUNDAMENTAL
RELATIVE VALUATION
RISK
PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

  • Score on 10-point scale
  • Ratings by analysts
  • Stock performance
JOIN ET PRIME

Medicamen Bio Financials

  • Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Income45.0343.6347.8947.3344.09
    Total Income Growth (%)3.20-8.881.177.354.18
    Total Expenses42.0441.3743.3443.4140.72
    Total Expenses Growth (%)1.60-4.55-0.166.6211.01
    EBIT3.002.264.543.923.37
    EBIT Growth (%)32.51-50.2015.9216.23-40.22
    Profit after Tax (PAT)1.461.352.132.031.48
    PAT Growth (%)7.79-36.504.8237.46-62.59
    EBIT Margin (%)6.665.189.498.287.65
    Net Profit Margin (%)3.233.104.444.293.35
    Basic EPS (₹)0.710.631.611.601.17
    Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Income43.1342.0645.5545.0443.22
    Total Income Growth (%)2.56-7.671.144.205.72
    Total Expenses38.8738.3639.9640.3838.31
    Total Expenses Growth (%)1.31-3.99-1.045.3910.18
    EBIT4.273.695.594.664.91
    EBIT Growth (%)15.50-33.9520.11-5.13-19.68
    Profit after Tax (PAT)2.272.263.102.773.01
    PAT Growth (%)0.52-27.2512.18-8.16-31.81
    EBIT Margin (%)9.898.7812.2810.3411.35
    Net Profit Margin (%)5.265.376.816.146.97
    Basic EPS (₹)1.781.782.452.192.38
    FY 2024FY 2023FY 2022FY 2021FY 2020
    Total Revenue181.63143.33117.17113.47127.44
    Total Revenue Growth (%)26.7222.333.26-10.960.93
    Total Expenses168.56126.2899.0797.08109.46
    Total Expenses Growth (%)33.4727.472.06-11.320.66
    Profit after Tax (PAT)10.9314.8414.9012.1313.29
    PAT Growth (%)-26.36-0.3622.82-8.7410.52
    Operating Profit Margin (%)9.7414.1716.8815.4814.77
    Net Profit Margin (%)6.0910.5312.9010.7610.59
    Basic EPS (₹)7.5011.9212.199.9310.94
    FY 2024FY 2023FY 2022FY 2021FY 2020
    Total Revenue174.69140.35117.17110.90119.25
    Total Revenue Growth (%)24.4719.785.65-7.00-5.55
    Total Expenses157.80123.0199.0694.15102.65
    Total Expenses Growth (%)28.2824.185.22-8.28-5.60
    Profit after Tax (PAT)13.3015.0014.9112.4912.26
    PAT Growth (%)-11.360.6419.381.861.94
    Operating Profit Margin (%)12.3314.6916.8916.1714.63
    Net Profit Margin (%)7.7110.8812.9111.3310.44
    Basic EPS (₹)10.5012.0412.2010.2210.09

    All figures in Rs Cr, unless mentioned otherwise

    Insights
    • Beating 3 Yr Revenue CAGR

      Company's annual revenue growth of 26.72% outperformed its 3 year CAGR of 16.79%. (Source: Consolidated Financials)
    • Employee & Interest Expense

      Company has spent 2.45% of its operating revenues towards interest expenses and 16.77% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
  • AnnualFY 2024FY 2023FY 2022FY 2021FY 2020
    Total Assets294.55278.52225.69194.01181.28
    Total Assets Growth (%)5.7623.4116.337.0232.72
    Total Liabilities87.5785.1079.2261.1260.07
    Total Liabilities Growth (%)2.897.4229.631.7520.23
    Total Equity206.98193.41146.47132.89121.22
    Total Equity Growth (%)7.0232.0510.229.6339.92
    Current Ratio (x)1.891.981.691.801.84
    Total Debt to Equity (x)0.150.130.170.130.08
    Contingent Liabilities-----
    AnnualFY 2024FY 2023FY 2022FY 2021FY 2020
    Total Assets294.21276.78225.70192.47176.46
    Total Assets Growth (%)6.3022.6317.279.0729.19
    Total Liabilities85.0182.9977.6658.1253.98
    Total Liabilities Growth (%)2.436.8633.627.678.05
    Total Equity209.21193.80148.04134.35122.48
    Total Equity Growth (%)7.9530.9110.199.6941.38
    Current Ratio (x)1.851.961.701.841.93
    Total Debt to Equity (x)0.140.130.160.130.08
    Contingent Liabilities8.948.565.854.736.35

    All figures in Rs Cr, unless mentioned otherwise

  • AnnualFY 2024FY 2023FY 2022FY 2021FY 2020
    Net Cash flow from Operating Activities-6.74-6.294.1112.7712.80
    Net Cash used in Investing Activities-5.56-5.88-8.47-17.81-37.29
    Net Cash flow from Financing Activities6.3129.134.305.8419.06
    Net Cash Flow-5.9916.95-0.070.80-5.43
    Closing Cash & Cash Equivalent14.7920.783.823.893.09
    Closing Cash & Cash Equivalent Growth (%)-28.84443.27-1.6925.80-63.70
    Total Debt/ CFO (x)-4.57-3.845.931.360.78
    AnnualFY 2024FY 2023FY 2022FY 2021FY 2020
    Net Cash flow from Operating Activities-0.25-3.504.8113.2911.71
    Net Cash used in Investing Activities-8.71-7.54-8.47-18.12-39.35
    Net Cash flow from Financing Activities3.1427.674.395.6821.36
    Net Cash Flow-5.8216.630.730.85-6.29
    Closing Cash & Cash Equivalent14.6220.443.813.082.23
    Closing Cash & Cash Equivalent Growth (%)-28.48435.8723.6838.12-73.79
    Total Debt/ CFO (x)-120.17-6.915.061.300.85

    All figures in Rs Cr, unless mentioned otherwise

    Insights
    • Decrease in Cash from Investing

      Company has used Rs 5.56 cr for investing activities which is an YoY decrease of 5.4%. (Source: Consolidated Financials)
  • AnnualFY 2024FY 2023FY 2022FY 2021FY 2020
    Return on Equity (%)5.287.7710.179.1210.96
    Return on Capital Employed (%)8.3210.1912.7412.4014.86
    Return on Assets (%)3.715.326.606.257.33
    Interest Coverage Ratio (x)5.599.0118.0416.4132.63
    Asset Turnover Ratio (x)0.630.560.5558.0969.23
    Price to Earnings (x)44.6456.1852.9154.0516.61
    Price to Book (x)2.354.355.374.911.82
    EV/EBITDA (x)20.4831.6231.9433.3310.82
    EBITDA Margin (%)13.7018.6921.8817.7216.77
    AnnualFY 2024FY 2023FY 2022FY 2021FY 2020
    Return on Equity (%)6.357.7810.069.2910.00
    Return on Capital Employed (%)10.0310.3112.6112.5213.62
    Return on Assets (%)4.515.426.606.486.94
    Interest Coverage Ratio (x)6.469.1018.0516.7430.21
    Asset Turnover Ratio (x)0.600.550.5557.2266.49
    Price to Earnings (x)36.7655.5652.9152.3618.02
    Price to Book (x)2.334.305.314.861.80
    EV/EBITDA (x)17.7631.3131.9232.7811.62
    EBITDA Margin (%)16.4019.2921.8918.4616.76

Found Financials useful?

Medicamen Bio Technicals

Medicamen Bio Peer Comparison

Insights
  • Stock Returns vs Nifty Smallcap 100

    Stock gave a 3 year return of -43.88% as compared to Nifty Smallcap 100 which gave a return of 48.97%. (as of last trading session)
  • Stock Returns vs Nifty Pharma

    Stock generated -43.88% return as compared to Nifty Pharma which gave investors 62.52% return over 3 year time period. (as of last trading session)

Medicamen Bio Shareholding Pattern

  • CategoryNo. of SharesPercentage% Change QoQ
    Promoters54,66,09542.99 %0.00
    Pledge00.00 %0.00
    FII6,6580.06 %0.00
    DII1,10,0000.87 %-0.29
    MF760.00 %0.00
    Others71,31,84756.08 %0.30
  • Category31 Dec 202430 Sep 202430 Jun 202431 Mar 2024
    Promoters42.9942.9942.9943.21
    Pledge0.000.000.000.00
    FII0.060.060.060.12
    DII0.871.171.170.99
    Mutual Funds0.000.000.000.00
    Others56.0855.7755.7755.68

Mutual Funds Ownership

No Data Available

Corporate Actions

  • Board Meeting

    Quarterly Results

    Nov 07, 2024

    General Meeting

    Rs.1.0000 per share(10%)Final Dividend & A.G.M.

    Aug 16, 2024

    Board Meeting

    Quarterly Results

    Aug 07, 2024

  • Announced onMeeting on
    Nov 07, 2024Nov 14, 2024
    Quarterly Results
    Aug 07, 2024Aug 13, 2024
    Quarterly Results
    May 21, 2024May 29, 2024
    Audited Results & Final Dividend
    Feb 05, 2024Feb 12, 2024
    Quarterly Results
    Nov 02, 2023Nov 10, 2023
    Quarterly Results
  • Announced onEx-DateDividend%
    May 29, 2024Sep 19, 202410%
    Aug 11, 2023Sep 20, 202310%
    May 25, 2022Sep 19, 202210%
    Jun 28, 2021Sep 16, 202110%
    Jun 30, 2020Sep 17, 20205%
  • No Data Available

  • No Data Available

  • No Data Available

  • Announced onMeeting on
    Aug 16, 2024Sep 25, 2024
    Rs.1.0000 per share(10%)Final Dividend & A.G.M.
    Aug 11, 2023Sep 27, 2023
    Rs.1.0000 per share(10%)Final Dividend & A.G.M.
    Sep 11, 2020Sep 25, 2020
    Book closure from Sep 19, 2020 to Sep 25, 2020
    Sep 03, 2019Sep 25, 2019
    -
    Apr 15, 2019May 06, 2019
    -

About Medicamen Bio

Medicamen Biotech Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 592.95 Crore) operating in Pharmaceuticals sector.

Show More

Key Indices Listed On

BSE AllCap

Address

1506, Chiranjiv Tower,43, Nehru Place,New Delhi, Delhi - 110019

Executive Leadership

RB

Rahul Bishnoi

Chairman
RM

Rajesh Madan

Chief Executive Officer
AK

Ashwani Kumar Sharma

Non Executive Director
SB

Sanjay Bansal

Non Executive Director
Show More

Auditors

Rai Qimat & Associates

FAQs about Medicamen Bio share

  • 1. What's the Medicamen Bio share price today?
    As of today Medicamen Bio share price is up by 1.74% basis the previous closing price of Rs 453.15. Medicamen Bio share price was Rs 466.35. Return Performance of Medicamen Bio Shares:
    • 1 Week: Medicamen Bio share price moved down by 0.48%
    • 1 Month: Medicamen Bio share price moved down by 9.00%
    • 3 Month: Medicamen Bio share price moved down by 13.04%
    • 6 Month: Medicamen Bio share price moved up by 7.45%
  • 2. What are the Medicamen Bio quarterly results?
    Total Revenue and Earning for Medicamen Bio for the year ending 2024-03-31 was Rs 181.63 Cr and Rs 10.93 Cr on Consolidated basis. Last Quarter 2024-09-30, Medicamen Bio reported an income of Rs 45.03 Cr and profit of Rs 1.46 Cr.
  • 3. Who are the key owners of Medicamen Bio stock?
    Following are the key changes to Medicamen Bio shareholding:
    • Promoter holding have gone down from 43.21 (31 Mar 2024) to 42.99 (31 Dec 2024)
    • Domestic Institutional Investors holding have gone down from 0.99 (31 Mar 2024) to 0.87 (31 Dec 2024)
    • Foreign Institutional Investors holding have gone down from 0.12 (31 Mar 2024) to 0.06 (31 Dec 2024)
    • Other investor holding has gone up from 55.68 (31 Mar 2024) to 56.08 (31 Dec 2024)
  • 4. What is the PE & PB ratio of Medicamen Bio?
    The PE ratio of Medicamen Bio stands at 84.17, while the PB ratio is 2.92.
  • 5. What is the CAGR of Medicamen Bio?
    The CAGR of Medicamen Bio is 12.31.
  • 6. What are the returns for Medicamen Bio share?
    Return Performance of Medicamen Bio Shares:
    • 1 Week: Medicamen Bio share price moved down by 0.48%
    • 1 Month: Medicamen Bio share price moved down by 9.00%
    • 3 Month: Medicamen Bio share price moved down by 13.04%
    • 6 Month: Medicamen Bio share price moved up by 7.45%
  • 7. Who is the CEO of Medicamen Bio?
    Rajesh Madan is the Chief Executive Officer of Medicamen Bio
  • 8. What is the market cap of Medicamen Bio?
    Medicamen Bio share has a market capitalization of Rs 582.84 Cr. Within Pharmaceuticals sector, it's market cap rank is 84.
  • 9. What is 52 week high/low of Medicamen Bio share price?
    Medicamen Bio share price saw a 52 week high of Rs 630.00 and 52 week low of Rs 355.45.
  • 10. Who's the chairman of Medicamen Bio?
    Rahul Bishnoi is the Chairman of Medicamen Bio
  • 11. What dividend is Medicamen Bio giving?
    An equity Final dividend of Rs 1 per share was declared by Medicamen Biotech Ltd. on 29 May 2024. So, company has declared a dividend of 10% on face value of Rs 10 per share. The ex dividend date was 19 Sep 2024.
  • 12. How can I quickly analyze Medicamen Bio stock?
    Key Metrics for Medicamen Bio are:
    • PE Ratio of Medicamen Bio is 83.68
    • Price/Sales ratio of Medicamen Bio is 2.72
    • Price to Book ratio of Medicamen Bio is 2.83
  • 13. Who are the peers for Medicamen Bio in Pharmaceuticals sector?
    Top 10 Peers for Medicamen Bio are Kilitch Drugs(I) Ltd., Zim Laboratories Ltd., Lyka Labs Ltd., SMS Lifesciences India Ltd., Venus Remedies Ltd., Brooks Laboratories Ltd., Wanbury Ltd., Medico Remedies Ltd., Ind-Swift Laboratories Ltd. and Albert David Ltd.

Top Gainers

As on 03:59 PM | 01 Feb 2025
Blue Star
2,056.65
239.11 (13.16%)
Zensar Tech
967.75
97.75 (11.24%)
Godfrey Philips
4,984.60
467.21 (10.35%)
Avenue Supermart
4,023.75
359.10 (9.80%)
Radico Khaitan
2,380.20
201.80 (9.27%)

Top Losers

As on 03:59 PM | 01 Feb 2025
Ircon Intl.
200.88
-20.56 (-9.29%)
RVNL
433.55
-42.75 (-8.98%)
NCC
231.60
-20.71 (-8.21%)
JSW Energy
472.00
-36.61 (-7.20%)
Railtel Corp
378.65
-27.96 (-6.88%)

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.